E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Transcultural, transdiagnostic, and concurrent validity of a revised metacognitions about symptoms control scale.
Fernie, Bruce A, Aoun, Amanda, Kollmann, Josianne et al. · Clinical psychology & psychotherapy · 2019 · DOI
Quick Summary
This study created a new questionnaire called the MaSCS-R to measure how people with chronic fatigue syndrome, fibromyalgia, and diabetes think about controlling their symptoms. Researchers tested the questionnaire in three languages (English, German, and Arabic) with over 500 patients. They found that negative thoughts about symptom control were linked to higher levels of anxiety, depression, and symptom severity across all three patient groups.
Why It Matters
Understanding the role of metacognitions—how people think about their symptoms—may help explain why anxiety and depression are so common in ME/CFS and related illnesses. This validated measurement tool could enable future research to better target psychological interventions and improve treatment outcomes for ME/CFS patients worldwide.
Observed Findings
- Metacognitive beliefs about symptom control were significantly associated with anxiety across CFS, fibromyalgia, and type 1 diabetes samples.
- Metacognitive factors showed concurrent validity with depression severity in all three patient groups.
- The MaSCS-R demonstrated configural and metric invariance across languages and diagnostic groups.
- Symptom severity was linked to metacognitive beliefs across all three conditions.
- The revised scale maintained adequate psychometric properties with a reduced 8-item format.
Inferred Conclusions
- Metacognitions about symptom control are a transdiagnostic mechanism relevant to anxiety and depression across multiple chronic illnesses.
- The MaSCS-R is a valid, culturally applicable tool for measuring symptom-related metacognitions in diverse populations.
- Metacognitive beliefs warrant consideration as a target for psychological interventions in chronic illness.
Remaining Questions
- Does changing metacognitions through therapy actually reduce anxiety, depression, or symptom severity in ME/CFS patients?
- Are certain metacognitive patterns more prevalent or problematic in ME/CFS compared to fibromyalgia or diabetes?
What This Study Does Not Prove
This study does not prove that negative metacognitions cause anxiety, depression, or symptom worsening; it only shows they occur together. The cross-sectional design means we cannot determine whether metacognitions change symptom severity or vice versa. The study also does not test whether changing metacognitions actually improves symptoms or distress.
Tags
Symptom:Fatigue
Method Flag:Weak Case DefinitionMixed Cohort
Metadata
- DOI
- 10.1002/cpp.2367
- PMID
- 30927302
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →